Effective Diagnosis and Treatment
of Early Parkinson’s Disease
A continuing medical education activity sponsored by NAMCP and AAMCN

This activity is an archive of the live session held at the 2009 Fall Managed Care Forum.
If you participated in the live activity, you are not eligible for
continuing education credits from this archive.

This activity is valid from January 20, 2010 to December 31, 2010
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from UCB Pharmaceuticals.
PLEASE CLICK HERE TO VIEW PRESENTATION

 PLEASE CLICK HERE FOR POST TEST AND EVALUATION

Instructions for CME/CEU: View the presentation, answer the post test, complete the evaluation form and submit to keads@namcp.org. A score of 70% must be achieved on the post test to received continuing education credits. You will have the option on the post test/evaluation page to submit your forms electronically or by faxing them to Katie Eads at 804-747-5316.

Goal
The goal of this activity is to provide medical directors from plans, purchasers and provider systems and nurse case managers with appropriate education on early Parkinson’s Disease and its impact on managed care environments.

Description
The session will provide important insights into effective management, including diagnosis and treatment of early PD. This educational activity will help attendees identify patients in need of early treatment and to distinguish disease progression from suboptimal treatment outcomes with the goal of improving patient care. It is imperative that Managed Care Medical Directors, Neurologists, Nurses and Healthcare Executives, who will be present at the Fall Managed Care Forum, learn about these advances in treatment and how to integrate them into their respective plan or provider organizations.

Upon Completion of this activity, participants will be able to:

  • Identify patients with Parkinson's disease (PD) in need of early treatment

  • Distinguish disease progression from suboptimal treatment of PD

  • Explain the role of the dopamine pathway in PD

  • Evaluate the considerations and challenges when initiating treatment for Parkinson's disease

  • Describe the efficacy, safety, and tolerability of different treatment options that may be used in early disease

Faculty: Larry Elmer, MD, PhD
Professor, Director, Parkinson’s Disease & Movement Program
University of Toledo, College of Medicine
   

Disclosure:

 Dr. Elmer has received honoraria or consulting fees from Boehringer Ingelheim, GlaxoSmithKline, Novartis, Teva Neuroscience, UCB, Valeant and Vernalis; he has received grant support from GlaxoSmithKline.
  The NAMCP planning committee has no real or perceived financial relationships to disclose.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. NAMCP designates this activity for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses (AAMCN) has been approved as a provider of continuing education by the Virginia Nurses Association (VNA). VNA is accredited as an approver of continuing education in nursing by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity will be awarded 1.0 contact hours.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from UCB Pharmaceuticals.